Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “alogliptin” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 15
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 15 pipeline programs matching "alogliptin" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

15 results for “alogliptin” Back to intelligence hub

Search results

  1. Alogliptin

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    5 trials
  2. Alogliptin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    9 trials
  3. Alogliptin Benzoate

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial
  4. Alogliptin and glimepiride

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials
  5. Alogliptin and glyburide

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial
  6. Alogliptin and insulin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial
  7. Alogliptin and metformin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial
  8. Alogliptin and metformin

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial
  9. Alogliptin and pioglitazone

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials
  10. Alogliptin and pioglitazone

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    2 trials
  11. Alogliptin and voglibose

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials
  12. Alogliptin

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials
  13. Alogliptin

    Takeda

    Pharmacokinetics and Pharmacodynamics

    phase 1 small molecule completed

    1 trial
  14. Alogliptin

    Takeda

    Diabetes Mellitus, Type 2

    approved small molecule completed

    6 trials
  15. alogliptin+pioglitazone

    Takeda

    Diabetes Mellitus, Type 2

    approved small molecule terminated

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.